Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients
Condition: Obesity
Intervention: Dietressa; Placebo
Intervention description: Comparison of different dosages (frequency) of drug; Placebo either (2 tablets 3 times daily) or
(1 tablet 6 times daily)
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 493.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No

Summary:

      The purpose of this study is:

        -  To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in
           treatment of obese patients.

        -  To assess clinical efficacy of Dietressa in the dose of 6 tablets daily within 24 weeks
           of therapy in reducing body weight in obese patients.

        -  To compare clinical efficacy of two dosage patterns for Dietressa (1 tablet 6 times
           daily and 2 tablets 3 times daily) within 24 weeks in treatment of obese patients.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Outpatient subjects with BMI 30,0-34,9 kg/m2.

          2. Male or female subjects aged 18 to 65 inclusive.

          3. Use of and compliance with contraception methods by patients of reproductive age, of
             both sexes.

          4. Presence of the patient's information sheet (informed consent form) for participation
             in the clinical trial.

        Exclusion Criteria:

          1. Symptomatic (secondary) obesity:

               -  with established genetic defect (including as a part of known genetic syndromes
                  affecting multiple organs): Prader-Willi syndrome, Alstrom's syndrome,
                  Laurence-Moon-Biedl syndrome, Dercum's syndrome etc.

               -  cerebral (adiposogenital dystrophy, Babinski-Frohlich syndrome): brain tumors;
                  dissemination of systemic lesions, infectious diseases; against mental diseases.

               -  endocrine: hypothyroid; hypoovarial; pituitary-hypothalamic disorders;
                  adrenopathy.

               -  iatrogenic (caused by drug administration, namely, insulin, glucocorticosteroids,
                  neuroleptics etc.).

          2. Compliance with a diet prescribed and monitored by the doctor to reduce body weight
             within 6 months before enrollment.

          3. Participation in the lifestyle modification program within 6 months before enrollment.

          4. Patients who quit smoking within 6 months before enrollment, or intending to quit
             smoking during the period of participation in the trial, as well as intending to begin
             smoking during the trial.

          5. Uncontrolled arterial hypertension (patients with 1-3 degree AH, receiving no adequate
             antihypertensive therapy).

          6. Type 1 and 2 diabetes mellitus.

          7. Edema syndrome with various etiology (chronic cardiac failure, nephrotic syndrome,
             hepatic cirrhosis).

          8. Circulatory failure, IIА degree and above.

          9. Decompensated cardiovascular disease, liver, kidney or gastrointestinal tract disease,
             metabolic, respiratory, endocrine, hematologic disease, peripheral vessel disease or
             another medical state. Oncological disease.

         10. Diseases and states, which, in the investigator's opinion, may prevent the patient
             from participating in the trial.

         11. Past history of bulimia / non-drug abepithymia.

         12. Past history of any bariatric surgeries.

         13. Lipoplasty underwent less then 1 year prior to screening visit, or cavitary surgery
             less then 6 months prior to screening visit.

         14. Surgeries scheduled within 6 months.

         15. Allergy to/intolerance of any of the drug components used during treatment.

         16. Malabsorption syndrome, including congenial or acquired lactase or another
             disaccharidase insufficiency.

         17. Administration of drugs specified as "Prohibited concomitant therapy", within 6 months
             before enrollment.

         18. Pregnancy, breast-feeding, unwillingness to comply with contraception methods during
             the trial and within 30 days after completion of participation in the trial.

         19. Drug and alcohol consumption (over 2 alc. units daily), mental diseases. Legal
             incapacity or limited legal capacity.

        21. Patients, who, in the investigator's opinion, will fail to observe the requirements
        during the trial or adhere to the studied drug administration procedure.

        22. Participation in other clinical trials within 3 months before enrolment in this trial.

        23. Presence of other factors, complicating the patient's participation in the trial (e.g.,
        planned lengthy business and other trips). 24. A patient is a part of the center's research
        staff, taking a direct part in the trial, or an immediate family member of the
        investigator. Immediate family members are defined as spouses, parents, children or
        siblings, regardless of whether full blood or adopted.

        25. The patient is employed with Scientific Production Firm Materia Medica Holding LLC,
        i.e. is the company's employee, part-time employee under contract, or appointed official in
        charge of the trial, or their immediate family.